Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
Company was hoping to position Lusedra as an anesthetic that did not require the presence of an anesthesiologist.
You may also be interested in...
Auxilium Xiaflex's Advisory Committee To Focus On Physician Expertise, Training
Majority of clinical trial investigators were hand or orthopedic surgeons and FDA asks if this level of expertise is needed to safely use the biologic.
Auxilium Xiaflex's Advisory Committee To Focus On Physician Expertise, Training
Majority of clinical trial investigators were hand or orthopedic surgeons and FDA asks if this level of expertise is needed to safely use the biologic.
FDA Rejects Eisai’s Aquavan Injection
Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.